Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Ms. Beckman oversees finance, investor relations and business development. Prior to joining Tango, Ms. Beckman was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. She also served as Interim Chief Financial Officer for Neon Therapeutics. Previously, Ms. Beckman was Chief Financial Officer of Idenix Pharmaceuticals, responsible for finance, investor relations and IT until it was acquired by Merck in 2014. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers (PwC). Ms. Beckman received her BA in business administration and accounting from Boston University and is a Certified Public Accountant in Massachusetts. In addition to Vor, Ms. Beckman also serves on the Board of Directors of Translate Bio as Chair of the Audit and the Nomination and Governance Committees.